CTC removal for advanced pancreatic or colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a blood-filtering device that removes circulating tumor cells (CTCs) from your blood. It is for people with metastatic pancreatic or colorectal cancer who have run out of standard chemo options or cannot take chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have metastatic pancreatic or colorectal cancer that has progressed after standard chemotherapy or you cannot have chemo.
- You are in fairly good health, able to care for yourself (ECOG score 0-2).
- You have at least 5 circulating tumor cells per milliliter of blood.
- You can have a small tube placed in a large vein for the blood-filtering procedure.
- You are not pregnant, breastfeeding, and agree to use effective birth control if needed.
- You are not at high risk for bleeding (platelets >50, INR <1.5) and your blood pressure is stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial checks whether a blood test that looks at tumor cells can help guide treatment for people with breast cancer. If you join, your care team will follow your responses over time to see if this “phenotype surveillance” approach is useful.
This trial is for people with colorectal cancer whose ctDNA blood test is still positive after surgery and chemotherapy. It tests two immunotherapy drugs (cemiplimab alone or with fianlimab) to see if they can eliminate the remaining cancer cells and prevent the cancer from coming back.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
Hear when a new Pancreatic Ductal Adenocarcinoma (mPDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.